Prenetics Global Limited (PRE)
| Market Cap | 369.92M +97.4% |
| Revenue (ttm) | 154.59M +171.0% |
| Net Income | -47.00M |
| EPS | -2.93 |
| Shares Out | 16.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,952 |
| Open | 22.01 |
| Previous Close | 22.00 |
| Day's Range | 20.91 - 22.40 |
| 52-Week Range | 11.37 - 27.24 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 35.86 (+64.19%) |
| Est. Earnings | Nov 9, 2026 |
About PRE
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Financial Performance
In 2025, Prenetics Global's revenue was $92.39 million, an increase of 479.76% compared to the previous year's $15.94 million. Losses were -$37.71 million, -18.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PRE stock is "Strong Buy." The 12-month stock price target is $35.86, which is an increase of 64.19% from the latest price.
News
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on September 22, 2026, providing details about a securities offering with the SEC.
Craig-Hallum bullish on Prenetics, initiates with a Buy
As previously reported, Craig-Hallum analyst Eric Des Lauriers initiated coverage of Prenetics (PRE) with a Buy rating and $40 price target Despite becoming the quickest supplement brand to reach $100...
Prenetics initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Prenetics (PRE) with a Buy rating and $40 price target
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on September 8, 2026, providing details about a securities offering with the SEC.
Prenetics initiated with a Buy at B. Riley
B. Riley initiated coverage of Prenetics (PRE) with a Buy rating and $37 price target The firm says its investment thesis is predicated upon Prenetics becoming U.S.-domiciled. The company transformed…
Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
Cumulative Personal Investment by Leadership Since November 2025 Reaches Approximately $3.75 Million NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or ...
Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
— Lily is IM8's first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across...
Prenetics Global Earnings Call Transcript: Q2 2026
Q2 revenue grew 29% sequentially to $46.5M, with IM8 at $45M and 65% gross margin. July marked the first positive adjusted free cash flow month, driven by strong subscriber growth and a $1B General Catalyst funding. Full-year revenue guidance was raised to $220M–$230M, with new product launches representing further upside.
Prenetics Global Slides: Q2 2026
Prenetics Global has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 18, 2026.
Prenetics Global Shareholder letter: Q2 2026
Prenetics Global has published a letter to shareholders covering Q2 2026, which was released on August 18, 2026.
Prenetics Global Earnings release: Q2 2026
Prenetics Global released its Q2 2026 earnings on August 18, 2026, summarizing the period's financial results.
Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond
Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Co
Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director
30+ years as one of Wall Street's top-ranked equity research consumer analysts, including leadership of U.S. consumer research at UBS Caroline will also serve on the Audit Committee, Compensation Comm...
Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Prenetics price target raised to $35 from $29 at Lake Street
Lake Street analyst Ryan Meyers raised the firm’s price target on Prenetics (PRE) to $35 from $29 and keeps a Buy rating on the shares. The structure of the $1B…
Prenetics price target raised to $40 from $30 at Benchmark
Benchmark raised the firm’s price target on Prenetics (PRE) to $40 from $30 and keeps a Buy rating on the shares after the company announced the closing of $1B in…
Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF)
IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27 sec...
Prenetics ups IM8 sales outlook amid growth financing, Bloomberg says
David Beckham and Prenetics (PRE)’ IM8 has lined up around $1B in growth financing from General Catalyst, Swetha Gopinath of Bloomberg reports, citing a statement. General Catalyst’s Customer Value Fu...
Prenetics Global Slides: Corporate presentation
Prenetics Global has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Prenetics initiated with a Buy at Benchmark
Benchmark initiated coverage of Prenetics (PRE) with a Buy rating and $30 price target The health and wellness company is focused on IM8, its consumer brand addressing the growing nutritional…
Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue
Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million , up 23.1% from IM8 revenue of $27.4 million in Q4 2025 and nearly 6x year-over-year from IM8 revenue of $5.7 million in Q1 2025 Rais...
Prenetics Global Earnings release: Q1 2026
Prenetics Global released its Q1 2026 earnings on June 10, 2026, summarizing the period's financial results.
Prenetics Global Slides: Q1 2026
Prenetics Global has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 10, 2026.
MEXC SPACEX(PRE) Launchpad Subscriptions Exceed $173M Across Two Phases
Second phase of the SPACEX(PRE) Launchpad attracted over 36,000 users, with total subscription volume surpassing $117 million, subscription volume $173M